Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013

Maturitas

Volumn 75, Issue 4, 2013, Pages 392-396

  Compston, J ⁱ   Bowring, C ^j   Cooper, A ^c   Cooper, C ^e,f,g   Davies, C ^j   Francis, R ^a   Kanis, J A ^h   Marsh, D ^k   McCloskey, E V ^d   Reid, D M ^b   Selby, P ^l  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Bridge Medical Centre   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f University Hospital Southampton NHS Foundation Trust   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j National Osteoporosis Society   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l MANCHESTER ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

Fracture; FRAX; Guideline; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; GLUCOCORTICOID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PREDNISOLONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CALCIUM INTAKE;

ARTICLE; CLINICAL PRACTICE; FRAGILITY FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK FACTOR; SPINE FRACTURE; VITAMIN SUPPLEMENTATION; AGED; CALCIUM INTAKE; CHEMICALLY INDUCED; FEMALE; FRACTURE; MALE; MIDDLE AGED; RISK ASSESSMENT; THERAPEUTIC USE; UNITED KINGDOM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM, DIETARY; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; VITAMIN D;

EID: 84880265582     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2013.05.013     Document Type: Article

References (17)

1. J. Compston, A. Cooper, and C. Cooper Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Maturitas 62 2009 105 108
2. Osteoporosis, Clinical guideline for prevention and treatment, www.shef.ac.uk/NOGG, Updated May 2013.
3. J.A. Kanis on behalf of the World Health Organization Scientific Group Assessment of osteoporosis at the primary health-care level. Technical report 2008 WHO Collaborating Centre University of Sheffield, UK
4. ® and the assessment of fracture probability in men and women from the UK Osteoporosis International 19 2008 385 397
5. ® - assessment and intervention thresholds for the UK Osteoporosis International 19 2008 1395 1408
6. J.A. Kanis, H. Johansson, A. Oden, and E.V. McCloskey Guidance for the adjustment of FRAX according to the dose of glucocorticoids Osteoporosis International 22 2011 809 816
7. S. Lekamwasam, J.D. Adachi, and D. Agnusdei A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis Osteoporosis International 23 9 2012 2257 2276
8. M.J. Bolland, A. Avenell, and J.A. Baron Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis BMJ 341 2010 c3691
9. M.J. Bolland, A. Grey, A. Avenell, G.D. Gamble, and I.R. Reid Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis BMJ 342 2011 d2040
10. B. Abrahamsen, and O. Sahota Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ 342 2011 d2080
11. K. Li, R. Kaaks, J. Linseisen, and S. Rohrmann Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC-Heidelberg) Heart 98 2012 920 925
12. National Osteoporosis Society Vitamin D and bone health: a practical clinical guideline for patient management 2013 www.nos.org
13. D.M. Black, A.V. Schwartz, and K.E. Ensrud Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial JAMA: The Journal of the American Medical Association 296 2006 2927 2938 (Pubitemid 46021497)
14. P. Ravn, J.O. Christensen, M. Baumann, and B. Clemmesen Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment Bone 22 1998 559 564 (Pubitemid 28226872)
15. N.B. Watts, A. Chines, and W.P. Olszynski Fracture risk remains reduced one year after discontinuation of risedronate Osteoporosis International 19 2008 365 372 (Pubitemid 351199181)
16. D.M. Black, I.R. Reid, and S. Boonen The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) Journal of Bone and Mineral Research 27 2012 243 254
17. W.D. Leslie, L.M. Lix, and H. Johansson Does osteoporosis therapy invalidate FRAX for fracture prediction? Journal of Bone and Mineral Research 27 2012 1243 1251